Fenwick & West represented Corium International, Inc. (NAS: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, in its $40.3 million follow-on offering of common stock. Corium sold 6,440,000 shares of common stock including 840,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock, at a public offering price of $6.25 per share. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.
Jefferies LLC acted as the sole book-running manager for the offering. Guggenheim Securities, LLC acted as lead manager. Needham & Company, LLC, FBR Capital Markets & Co., H.C. Wainwright & Co., LLC and WBB Securities, LLC acted as co-managers.
The Fenwick transaction team included corporate partner Robert Freedman and associates Jennifer Hitchcock and Debbie Li.